Home Cart Sign in  
Chemical Structure| 1286770-55-5 Chemical Structure| 1286770-55-5

Structure of Verubecestat
CAS No.: 1286770-55-5

Chemical Structure| 1286770-55-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Verubecestat is a BACE1 inhibitor. MK-8931 binds significantly to β-secretase.

Synonyms: MK-8931

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Verubecestat

CAS No. :1286770-55-5
Formula : C17H17F2N5O3S
M.W : 409.41
SMILES Code : O=C(NC1=CC=C(F)C([C@@](C2)(C)N=C(N)N(C)S2(=O)=O)=C1)C3=NC=C(F)C=C3
Synonyms :
MK-8931
MDL No. :MFCD28963974
InChI Key :YHYKUSGACIYRML-KRWDZBQOSA-N
Pubchem ID :51352361

Safety of Verubecestat

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice AppG-F and AppNL-G-F mouse models Oral 10 mg/kg Single dose, analyzed after 3 hours To evaluate the inhibitory effect of Verubecestat on Aβ levels. Results showed that Verubecestat significantly reduced Aβ40 and Aβ42 levels in the cortices of AppG-F mice but not in AppNL-G-F mice. PMC9177067
Mice Wild-type mice Oral gavage 3 mg/kg Daily administration for 4 months To evaluate the effects of Verubecestat on learning and synaptic plasticity. Results showed that Verubecestat significantly reduced hippocampal LTP and cognitive behaviors. PMC8760050
Mice 5XFAD mouse model Oral 10, 30, and 100 mg/kg/day From 3 to 6 months of age, lasting 3 months To evaluate the prophylactic treatment effects of verubecestat in an AD mouse model, showing dose-dependent reductions in amyloid plaque deposition but no cognitive improvement and with side effects. PMC9281365
Mice Tg2576-AβPPswe transgenic mice Dietary administration 110 mg/kg/day Continuous for 12 weeks Verubecestat significantly suppressed the accumulation of total levels of brain Aβ40 and Aβ42 and Thioflavin S positive plaque load. Compared to controls, verubecestat-treated mice showed significantly reduced plaque load in the cortex and hippocampus without significantly increasing ARIA-H events. PMC5611839

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.44mL

0.49mL

0.24mL

12.21mL

2.44mL

1.22mL

24.43mL

4.89mL

2.44mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories